Risk of non-hypoglycemic agents for hypoglycemia-related hospitalization in patients with type 2 diabetes: a large-scale medical receipt database analysis
Authors' conclusion
This large retrospective analysis revealed that the risk of HRH from some non-hypoglycemic agents in patients with T2D may be increased. The results of this study are expected to support treatment planning by physicians and healthcare professionals involved in diabetes care.
Study context
- Population
- Japanese patients with T2D enrolled in the Medical Data Vision administrative claims database, April 2014–October 2019
- Participants
- 703,745 patients
- Exposure
- Use vs non-use of non-hypoglycemic agents associated with hypoglycemia
- Outcome
- Hypoglycemia-related hospitalization (HRH) due to non-hypoglycemic agents
Methodological detailsadministrative claims database, multivariate logistic regression
- Administrative claims database
- Multivariate logistic regression
Main finding
As reported in the abstract
HRH
- Patients who experienced hypoglycemia-related hospitalization (HRH)
- 10 376 (1.47%)
- Non-hypoglycemic agents associated with hypoglycemia
- 332
- Drugs with significant OR >1 for HRH
- 75
- Diazoxide, OR (95% CI) for HRH (highest)
- 15.5 (4.87 to 49.3)
- Methylphenidate, OR (95% CI) for HRH
- 5.15 (1.53 to 17.3)
- Disulfiram, OR (95% CI) for HRH
- 4.21 (2.05 to 8.62)
- Hydrocortisone, OR (95% CI) for HRH
- 2.89 (1.11 to 7.51)
Observational data: associations, not effects.
Original publication
Risk of non-hypoglycemic agents for hypoglycemia-related hospitalization in patients with type 2 diabetes: a large-scale medical receipt database analysis. BMJ Open Diabetes Res Care. Published 21 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →